Edgar Filing: CATALYST PHARMACEUTICALS, INC. - Form RW

CATALYST PHARMACEUTICALS, INC.

Form RW December 23, 2016

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle

Suite 1250

Coral Gables, Florida 33134

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Attention: Suzanne Hayes

Assistant Director

Office of Insurance and Healthcare

VIA EDGAR AND OVERNIGHT COURIER

Ladies and Gentlemen:

On behalf of Catalyst Pharmaceuticals, Inc., a Delaware corporation (the Company), we hereby request, pursuant to Section 477 of the Securities Act of 1933, as amended (the Securities Act), that Post-Effective Amendment No. 1 to the Company s Registration Statement on Form S-3, Registration No. 333-193699, filed with the Securities and Exchange Commission (SEC) on December 6, 2016 (the Post-Effective Amendment) be withdrawn effective immediately. The Post-Effective Amendment is being withdrawn at the request of the SEC and will be replaced by the filing of a new registration statement. The Post-Effective Amendment has not been declared effective and none of the Company s securities has been sold pursuant to the Post-Effective Amendment.

Accordingly, we request that the SEC issue an order granting the withdrawal of the Post-Effective Amendment (Order) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to Philip B. Schwartz, Esq. of Akerman LLP, via email at philip.schwartz@akerman.com or via facsimile at (305) 349-4833.

This withdrawal affects only the Post-Effective Amendment and does not otherwise affect the Company s Registration Statement on Form S-3, Registration No. 333-193699.

Should you have any questions regarding this request for withdrawal, please contact Philip B. Schwartz at (954) 468-2455.

Edgar Filing: CATALYST PHARMACEUTICALS, INC. - Form RW

/s/ Alicia Grande

Alicia Grande Chief Financial Officer Catalyst Pharmaceuticals, Inc.

cc: Philip B. Schwartz, Akerman LLP

Dorrie Yale, Securities and Exchange Commission

Mary Beth Breslin, Securities and Exchange Commission